Clinical Trial Update: Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured [Phase 1]

View source ↗

Summary

Phase 1 trial of an Ad-CCL-21–transduced, peptide-pulsed dendritic cell vaccine targeting MART-1, gp100, tyrosinase, and NY-ESO-1 in melanoma patients has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Adenovirus CCL-21 transduced MART-1/gp100/tyrosinase/NY-ESO-1 peptide-pulsed dendritic cells

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma (Skin) | Phase 1 | Status: COMPLETED